Depressive Disorders - Australia

  • Australia
  • Revenue in the Depressive Disorders market is projected to reach US$0.46bn in 2024.
  • Revenue is expected to show an annual growth rate (CAGR 2024-2028) of 2.11%, resulting in a market volume of US$0.50bn by 2028.
  • In global comparison, most revenue will be generated in the United States (US$6,263.00m in 2024).
  • In relation to total population figures, per person revenues of US$280.20 are generated in 2024.

Key regions: Japan, United Kingdom, China, Europe, Canada

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Depressive Disorders market in Australia is experiencing significant growth and development.

Customer preferences:
In recent years, there has been a growing awareness and understanding of mental health issues in Australia. As a result, there is an increasing demand for effective treatments and therapies for depressive disorders. Customers are seeking out a variety of options, including pharmaceutical drugs, therapy sessions, and alternative treatments such as meditation and mindfulness. The preference for personalized and holistic approaches to treatment is also on the rise, with many customers looking for solutions that address both the physical and psychological aspects of depression.

Trends in the market:
One of the key trends in the Depressive Disorders market in Australia is the increasing use of antidepressant medications. Pharmaceutical companies are constantly developing new and improved drugs to meet the growing demand. These medications are often prescribed in combination with therapy sessions to provide a comprehensive treatment plan for patients. Additionally, there is a growing trend towards the use of digital health solutions, such as mobile apps and online therapy platforms, which provide convenient and accessible support for individuals suffering from depressive disorders.

Local special circumstances:
Australia has a unique healthcare system that plays a significant role in the development of the Depressive Disorders market. The country has a universal healthcare system, known as Medicare, which provides subsidized access to a range of healthcare services, including mental health treatments. This accessibility and affordability of mental health services contribute to the increasing demand for treatments for depressive disorders. Additionally, Australia has a high prevalence of depressive disorders, which further drives the growth of the market.

Underlying macroeconomic factors:
The growing Depressive Disorders market in Australia is also influenced by several macroeconomic factors. The country has experienced a period of economic growth, which has resulted in increased disposable income for individuals. This has allowed more people to seek out and afford treatments for depressive disorders. Additionally, the aging population in Australia is contributing to the growth of the market, as older individuals are more likely to experience depressive disorders and require treatment. The government's focus on mental health and the provision of funding for research and development in the field also plays a role in the market's development.In conclusion, the Depressive Disorders market in Australia is experiencing growth and development due to increasing customer preferences for effective treatments, the use of antidepressant medications, the adoption of digital health solutions, the accessibility of mental health services through the country's healthcare system, and underlying macroeconomic factors such as economic growth and an aging population.

Methodology

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

Overview

  • Revenue
  • Patients
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)